Overview

Gender

male

Dr. Marc Lang, Head Medicinal Chemistry, has more than 30 years of experience in medicinal chemistry, of which some 20 years in Oncology and Immunology. He has contributed to three multi-billion Novartis compounds on market (Femara®, Reyataz® and Tasigna®), and five promising compounds in clinical trials. Until October 2012, he was Head of Medicinal Chemistry for Oncology research programs at Novartis Pharma AG.

Dr. Lang holds a Ph.D. in Chemistry from the University of Strasbourg and was a postdoctoral fellow at the Woodward Research Institute in Basel, Switzerland